---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004154"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:40:45.650134+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech posts FY2024 net loss of $55.9M; Checkpoint to be acquired by Sun Pharma

## Summary
- Net loss attributable to common stockholders of $55.9M ($2.69/sh) vs $68.7M ($8.47/sh) in FY2023; net revenue $57.7M, down from $84.5M.
- FDA approved Emrosi (rosacea) in Nov 2024 and UNLOXCYT (cSCC) in Dec 2024; commercial launch of Emrosi underway.
- Checkpoint to be acquired by Sun Pharma for $4.10/sh upfront plus up to $0.70 CVR; Fortress expects ~$28M at closing plus 2.5% royalty.
- FDA accepted CUTX-101 NDA for priority review with PDUFA date Sept 30, 2025.
- Cash $57.3M as of Dec 31, 2024; paused Series A Preferred dividends in July 2024, deferring ~$0.7M/month.

## SEC filing metadata
- accession: 0001558370-25-004154
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/0001558370-25-004154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004154
- JSON: https://secwatch.observer/filing/0001558370-25-004154.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.